Celltrion, the pioneering Korean biopharmaceuticals firm, has made a significant stride in the US market with the launch of its groundbreaking autoimmune disease treatment, Zymfentra. This new treatment, a subcutaneous injection formulation of Celltrion’s infliximab Remsima, marks a new era in the management of ulcerative colitis and Crohn’s disease for adults.
“The introduction of Zymfentra in the US is a pivotal moment for patients living with ulcerative colitis or Crohn’s disease,” remarked Thomas Nusbickel, chief commercial officer at Celltrion USA. “The convenience of subcutaneous administration represents a notable advancement in patient care, providing individuals in the US with greater flexibility in managing their conditions.”
Zymfentra’s wholesale acquisition cost for two injections, required over a four-week period, has been set at $6,181. This pricing strategy reflects Celltrion’s commitment to providing an optimal cost for the drug, taking into consideration its competitive landscape.
Celltrion’s strategic focus is now on expanding Zymfentra’s market share in the US inflammatory bowel disease market, which is estimated to be approximately 12.8 trillion won ($9.6 billion), according to data from health care researcher IQVIA. The company aims to achieve over 1 trillion won in annual sales with Zymfentra by 2025 and beyond, driving long-term revenue growth.
With Zymfentra’s patent protection secured until 2037 for its dosage form and 2040 for its route of administration, Celltrion is well-positioned to solidify its presence in the US market. The company is confident that Zymfentra’s efficacy and accessibility will resonate with patients, ultimately increasing its market share.
Michael Osso, president and CEO of the Crohn’s & Colitis Foundation, hailed the launch of Zymfentra as a significant advancement for eligible adult patients with Crohn’s disease and ulcerative colitis. “This innovative treatment option allows patients to receive Zymfentra at home, through subcutaneous delivery, providing them with more flexibility and choice in managing their conditions,” Osso noted.
As Celltrion embarks on this new chapter with Zymfentra, the company remains committed to transforming the lives of patients and advancing the field of autoimmune disease treatment.
(Source: KED Global | Korea Herald | Pharma Letter | KBR)
